Open Payments

Yale-New Haven Hospital

Type
Teaching hospital
Where
NEW HAVEN, CT
Medicare CCN
070022
Received
$1,414,381 in 187 records, 2023 ($217,344 general, $1,197,037 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment54$217,344
2023Research payment133$1,197,037

By company

CompanyRecordsAmountYears
SEAGEN INC.96$271,9952023
Novartis Pharmaceuticals Corporation9$265,7972023
GENZYME CORPORATION4$229,9362023
Gen-Probe, Inc.4$142,8262023
Sage Therapeutics, LLC1$119,2002023
TransMedics, Inc.7$107,2492023
National Marrow Donor Program4$60,0752023
PFIZER INC.17$53,2392023
Genentech USA, Inc.1$25,0002023
E.R. Squibb & Sons, L.L.C.3$22,2002023
Draeger Medical Systems, Inc2$17,9742023
GE HEALTHCARE1$16,8602023
CTI BioPharma Corp.1$15,0002023
KLS-Martin L.P.2$10,0532023
AstraZeneca Pharmaceuticals LP4$10,0002023
ClearPoint Neuro, Inc.1$8,5992023
Stryker Corporation1$8,4112023
Indivior Inc.6$5,4382023
Incyte Corporation1$5,0002023
Lilly USA, LLC1$5,0002023
Eisai Inc.1$5,0002023
Olympus America Inc.7$3,0912023
Eli Lilly and Company1$2,2482023
Abbott Laboratories1$2,2102023
Barco, Inc.1$1,0922023
Alexion Pharmaceuticals, Inc.6$6362023
ARRAY BIOPHARMA INC2$1502023
Grifols Diagnostic Solutions, Inc.2$962023

By nature of payment

NatureRecordsAmount
Research payment133$1,197,037
Compensation for services other than consulting, including serving as faculty or as a speaker at a v16$110,711
Space rental or facility fees (teaching hospital only)2$40,000
Grant4$27,200
Education21$16,596
Debt forgiveness9$13,145
Long term medical supply or device loan2$9,691

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-20SEAGEN INC.$1,950Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-12-18SEAGEN INC.$10,189Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-12-13SEAGEN INC.$5,200Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-12-13Alexion Pharmaceuticals, Inc.$140Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-12-08Draeger Medical Systems, Inc$17,791Research paymentCash or cash equivalentSTIMIT Activator 1 Pivotal Study (NCT05883163)2023
2023-11-17Abbott Laboratories$2,210Research paymentCash or cash equivalentDiamondback Coronary Device, VascularEvaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplas2023
2023-11-15SEAGEN INC.$5,000EducationCash or cash equivalentTUKYSA Drug, Oncology2023
2023-11-15SEAGEN INC.$5,000EducationCash or cash equivalentADCETRIS Biological, Oncology2023
2023-11-15SEAGEN INC.$2,340Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-11-15SEAGEN INC.$1,745Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-11-15SEAGEN INC.$1,740Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-11-15Indivior Inc.$601Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDCoordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT)2023
2023-11-09SEAGEN INC.$250Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-11-08SEAGEN INC.$390Research paymentCash or cash equivalentTIVDAK Biological, OncologyOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2023
2023-11-07Indivior Inc.$1,033Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDLong-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults2023
2023-11-03Stryker Corporation$8,411Research paymentCash or cash equivalentTRIATHLON Device, KNEESDOES THE SIZE OF THE COMPONENTS USED VARY WHEN ROBOTIC TKA IS PERFORMED COMPARED TO MANUAL TKA?2023
2023-11-02SEAGEN INC.$780Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-11-02SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-10-29Olympus America Inc.$11Debt forgivenessIn-kind items and services2023
2023-10-27Sage Therapeutics, LLC$119,200Research paymentCash or cash equivalentZULRESSO Drug, PSYCHIATRY/PSYCHOLOGYUtility of Brexanolone to target stress-induced alcohol use among men and women with Posttraumatic Stress Disorder2023
2023-10-25SEAGEN INC.$500Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-10-20National Marrow Donor Program$19,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-10-20TransMedics, Inc.$250Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART CAP2023
2023-10-11Alexion Pharmaceuticals, Inc.$151Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-10-11SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-10-10Novartis Pharmaceuticals Corporation$36,226Research paymentCash or cash equivalentKISQALI Drug, OncologyRibociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence2023
2023-10-04E.R. Squibb & Sons, L.L.C.$15,000GrantCash or cash equivalent2023
2023-10-04SEAGEN INC.$730Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-10-03Novartis Pharmaceuticals Corporation$600Research paymentIn-kind items and servicesA Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients Wit2023
2023-10-03Draeger Medical Systems, Inc$182Research paymentCash or cash equivalentSTIMIT Activator 1 Pivotal Study (NCT05883163)2023
2023-09-28TransMedics, Inc.$16,140Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEOCSHEART-01-ClinPAS2023
2023-09-20SEAGEN INC.$996Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-09-20SEAGEN INC.$500Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-09-20Alexion Pharmaceuticals, Inc.$137Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-09-15TransMedics, Inc.$54,129Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEOCSHEART-01-ClinPAS2023
2023-09-13SEAGEN INC.$4,615Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-09-13SEAGEN INC.$2,600Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-09-13SEAGEN INC.$1,500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-09-13SEAGEN INC.$650Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-09-06SEAGEN INC.$5,850Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-09-06SEAGEN INC.$3,289Research paymentCash or cash equivalentTIVDAK Biological, OncologyOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2023
2023-09-06SEAGEN INC.$2,891Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-09-06SEAGEN INC.$1,788Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-09-06SEAGEN INC.$585Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-09-06SEAGEN INC.$390Research paymentCash or cash equivalentTIVDAK Biological, OncologyOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2023
2023-09-06Alexion Pharmaceuticals, Inc.$35Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-09-05PFIZER INC.$75EducationIn-kind items and services2023
2023-09-05PFIZER INC.$75EducationIn-kind items and services2023
2023-09-01Lilly USA, LLC$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-08-24GENZYME CORPORATION$53,062Research paymentCash or cash equivalentXENPOZYME Biological, Genetic DiseaseUnderstanding the role of sphingomyelin and lyso-sphingomyelin accumulation in pathogenesis of Niemann Pick type B disea2023
2023-08-24GENZYME CORPORATION$53,062Research paymentCash or cash equivalentXENPOZYME Biological, Genetic DiseaseUnderstanding the role of sphingomyelin and lyso-sphingomyelin accumulation in pathogenesis of Niemann Pick type B disea2023
2023-08-24GENZYME CORPORATION$53,062Research paymentCash or cash equivalentXENPOZYME Biological, Genetic DiseaseUnderstanding the role of sphingomyelin and lyso-sphingomyelin accumulation in pathogenesis of Niemann Pick type B disea2023
2023-08-23SEAGEN INC.$876Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-08-23SEAGEN INC.$650Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-08-23Alexion Pharmaceuticals, Inc.$140Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-08-21GE HEALTHCARE$16,860Research paymentIn-kind items and servicesVizamyl Drug, CORE IMAGING2023
2023-08-16AstraZeneca Pharmaceuticals LP$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentIMFINZI Biological, Oncology2023
2023-08-16AstraZeneca Pharmaceuticals LP$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentENHERTU Biological, Oncology2023
2023-08-16AstraZeneca Pharmaceuticals LP$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentCALQUENCE Drug, Oncology2023
2023-08-16AstraZeneca Pharmaceuticals LP$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTAGRISSO Drug, Oncology2023
2023-08-16ARRAY BIOPHARMA INC$75EducationIn-kind items and services2023
2023-08-16PFIZER INC.$75EducationIn-kind items and services2023
2023-08-15PFIZER INC.$75EducationIn-kind items and services2023
2023-08-09SEAGEN INC.$2,600Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-08-09SEAGEN INC.$2,250Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-08-09SEAGEN INC.$500Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-08-09SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-08-08CTI BioPharma Corp.$15,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentVonjo Drug, Hematology2023
2023-08-07Indivior Inc.$1,298Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDLong-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults2023
2023-08-07PFIZER INC.$75EducationIn-kind items and services2023
2023-08-04National Marrow Donor Program$24,410Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-08-02E.R. Squibb & Sons, L.L.C.$6,000GrantCash or cash equivalent2023
2023-08-02SEAGEN INC.$1,788Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-08-02E.R. Squibb & Sons, L.L.C.$1,200GrantCash or cash equivalent2023
2023-08-02SEAGEN INC.$390Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-08-01PFIZER INC.$75EducationIn-kind items and services2023
2023-07-26SEAGEN INC.$1,500Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-07-26SEAGEN INC.$750Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-07-26SEAGEN INC.$500Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-07-26PFIZER INC.$150EducationIn-kind items and services2023
2023-07-26ARRAY BIOPHARMA INC$75EducationIn-kind items and services2023
2023-07-25PFIZER INC.$75EducationIn-kind items and services2023
2023-07-24PFIZER INC.$300EducationIn-kind items and services2023
2023-07-24PFIZER INC.$75EducationIn-kind items and services2023
2023-07-24PFIZER INC.$75EducationIn-kind items and services2023
2023-07-24PFIZER INC.$75EducationIn-kind items and services2023
2023-07-24PFIZER INC.$75EducationIn-kind items and services2023
2023-07-24PFIZER INC.$75EducationIn-kind items and services2023
2023-07-19SEAGEN INC.$6,614Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-07-19SEAGEN INC.$5,364Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-07-19SEAGEN INC.$1,788Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-07-19SEAGEN INC.$1,788Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-07-19SEAGEN INC.$1,500Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-07-19SEAGEN INC.$750Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-07-19SEAGEN INC.$500Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-07-19SEAGEN INC.$500Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-07-19SEAGEN INC.$390Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-07-19SEAGEN INC.$250Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-07-19Alexion Pharmaceuticals, Inc.$33Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-07-17SEAGEN INC.$8,400Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-07-17SEAGEN INC.$5,750Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-07-17SEAGEN INC.$1,170Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-07-17SEAGEN INC.$500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-07-17SEAGEN INC.$390Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-07-17SEAGEN INC.$390Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-07-12PFIZER INC.$12,837Research paymentCash or cash equivalentA PHASE 1 RANDOMIZED OPENLABEL 3PERIOD CROSSOVER SINGLEDOSE 2PART STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFEC2023
2023-07-12SEAGEN INC.$750Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-06-28Eisai Inc.$5,000GrantCash or cash equivalent2023
2023-06-28SEAGEN INC.$650Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-06-28SEAGEN INC.$650Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-06-26GENZYME CORPORATION$70,749Research paymentCash or cash equivalentXENPOZYME Biological, Genetic DiseaseUnderstanding the role of sphingomyelin and lyso-sphingomyelin accumulation in pathogenesis of Niemann Pick type B disea2023
2023-06-23PFIZER INC.$35,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-06-19Gen-Probe, Inc.$3,009Research paymentCash or cash equivalentPANTHER FUSION Device, DiagnosticsMethod Comparison Study Protocol for the Panther Fusion GI Panels2023
2023-06-07Indivior Inc.$865Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDLong-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults2023
2023-06-02SEAGEN INC.$500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-05-30SEAGEN INC.$1,170Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-05-22Gen-Probe, Inc.$22,367Research paymentCash or cash equivalentPANTHER FUSION Device, DiagnosticsMethod Comparison Study Protocol for the Panther Fusion GI Panels2023
2023-05-17Genentech USA, Inc.$25,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentPhesgo Biological, BioOncology2023
2023-05-17SEAGEN INC.$10,728Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-05-17SEAGEN INC.$9,477Research paymentCash or cash equivalentTIVDAK Biological, OncologyOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2023
2023-05-17SEAGEN INC.$1,856Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-05-17SEAGEN INC.$675Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-05-17SEAGEN INC.$250Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-05-17SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-05-17SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-05-10SEAGEN INC.$5,200Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-05-10Eli Lilly and Company$2,248Research paymentIn-kind items and servicesEMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIEN2023
2023-05-10SEAGEN INC.$1,500Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-05-10SEAGEN INC.$1,170Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-05-10SEAGEN INC.$1,170Research paymentCash or cash equivalentTIVDAK Biological, OncologyOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2023
2023-05-10SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-05-03SEAGEN INC.$16,049Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-05-03SEAGEN INC.$1,560Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-05-03SEAGEN INC.$390Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-05-01Grifols Diagnostic Solutions, Inc.$48EducationIn-kind items and services2023
2023-05-01Grifols Diagnostic Solutions, Inc.$48EducationIn-kind items and services2023
2023-04-28National Marrow Donor Program$8,980Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-04-17Gen-Probe, Inc.$10,500Research paymentCash or cash equivalentPANTHER FUSION Device, DiagnosticsMethod Comparison Study Protocol for the Panther Fusion GI Panels2023
2023-04-11Indivior Inc.$1,038Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDCoordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT)2023
2023-04-04Barco, Inc.$1,092Long term medical supply or device loanIn-kind items and services2023
2023-03-23PFIZER INC.$4,052Research paymentCash or cash equivalentA PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED 4PERIOD CROSSOVER FIRSTINHUMAN STUDY TO EVALUATE THE SAFE2023
2023-03-22SEAGEN INC.$19,640Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-03-22SEAGEN INC.$18,172Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-03-22SEAGEN INC.$5,364Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2023
2023-03-22SEAGEN INC.$2,016Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-03-22SEAGEN INC.$1,200Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-03-22SEAGEN INC.$780Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-03-20Gen-Probe, Inc.$106,950Research paymentCash or cash equivalentPANTHER FUSION Device, DiagnosticsMethod Comparison Study Protocol for the Panther Fusion GI Panels2023
2023-03-17TransMedics, Inc.$5,460Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART TRIAL2023
2023-03-17SEAGEN INC.$2,636Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-03-17SEAGEN INC.$1,300Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-03-17SEAGEN INC.$650Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-03-03Olympus America Inc.$11Debt forgivenessIn-kind items and services2023
2023-03-03Olympus America Inc.$1Debt forgivenessIn-kind items and services2023
2023-03-03Olympus America Inc.$1Debt forgivenessIn-kind items and services2023
2023-03-03Olympus America Inc.$0Debt forgivenessIn-kind items and services2023
2023-02-28Olympus America Inc.$2,000Debt forgivenessIn-kind items and services2023
2023-02-28Olympus America Inc.$1,066Debt forgivenessIn-kind items and services2023
2023-02-23TransMedics, Inc.$26,520Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART CAP2023
2023-02-23TransMedics, Inc.$4,500Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART TRIAL2023
2023-02-23TransMedics, Inc.$250Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART CAP2023
2023-02-22SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-02-22SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-02-20Novartis Pharmaceuticals Corporation$18,119Research paymentCash or cash equivalentKISQALI Drug, OncologyRibociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence2023
2023-02-15SEAGEN INC.$4,529Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-02-15SEAGEN INC.$2,354Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-02-15SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-02-13SEAGEN INC.$43,771Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-02-13SEAGEN INC.$1,500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-02-13SEAGEN INC.$375Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12023
2023-02-09KLS-Martin L.P.$7,858Debt forgivenessCash or cash equivalentIPS,IMPLANT, CRANIAL, 00088,CP TITANIUM,QTY:001 EA Device, Osteosynthesis2023
2023-02-09KLS-Martin L.P.$2,195Debt forgivenessCash or cash equivalentIPS,SUPPLEMENTAL MODEL, FULL, 00007,QTY:001 EA Device, Osteosynthesis2023
2023-02-08SEAGEN INC.$2,016Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2023
2023-01-27National Marrow Donor Program$7,585Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2023
2023-01-12Indivior Inc.$601Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDCoordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT)2023
2023-01-09Novartis Pharmaceuticals Corporation$130,353Research paymentCash or cash equivalentKISQALI Drug, OncologyRibociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence2023
2023-01-09Incyte Corporation$5,000EducationCash or cash equivalent2023
2023-01-04SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-01-04SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2023
2023-01-04SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-01-04SEAGEN INC.$146Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2023
2023-01-01Novartis Pharmaceuticals Corporation$75,096Research paymentCash or cash equivalentSingle-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investiga2023
2023-01-01ClearPoint Neuro, Inc.$8,599Long term medical supply or device loanIn-kind items and servicesCLEARPOINT Device, Neurology2023
2023-01-01Novartis Pharmaceuticals Corporation$2,916Research paymentIn-kind items and servicesA Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymp2023
2023-01-01Novartis Pharmaceuticals Corporation$1,920Research paymentIn-kind items and servicesA Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax 2023
2023-01-01Novartis Pharmaceuticals Corporation$345Research paymentIn-kind items and servicesA Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for th2023
2023-01-01Novartis Pharmaceuticals Corporation$220Research paymentIn-kind items and servicesA randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylatin2023

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

South Central Connecticut Planning RegionNew Haven city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
New Haven, CT
County
South Central Connecticut Planning Region, CT
State
Connecticut
Population B01003134,349570,5983,624,508
Population, 2020 census P1134,023-3,605,944
Median age B0100231.940.241.1
Under 18 B0100121.3%19.6%20.2%
65 and over B0100111.8%18.6%18.5%
Households B1100154,773230,6731,434,007
Foreign born B0500218.0%13.7%15.7%
Median household income B19013$56,851$88,197$95,781
Median family income B19113$68,668$115,384$122,706
Per capita income B19301$36,242$49,766$55,915
Poverty rate B1700123.9%11.4%10.0%
Unemployment rate B230258.4%6.0%5.6%
Civilian labor force B2302569,528307,6071,959,490
Mean commute (minutes) B0801321.523.526.5
Bachelor's degree or higher B1500338.9%42.0%42.5%
Housing units B2500160,333248,2671,541,822
Owner-occupied B2500328.4%60.5%66.5%
Renters B2500371.6%39.5%33.5%
Median home value B25077$287,100$353,100$366,900
Median gross rent B25064$1,488$1,525$1,488
White, not Hispanic B0300230.0%58.5%61.9%
Black B0300227.6%13.0%9.8%
Hispanic or Latino B0300231.0%19.5%18.3%
Asian B030025.2%4.5%4.7%
American Indian and Alaska Native B030020.2%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.